MCID: NSL008
MIFTS: 39

Nasal Cavity Cancer

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Nasal Cavity Cancer

MalaCards integrated aliases for Nasal Cavity Cancer:

Name: Nasal Cavity Cancer 12 15
Nasal Cavity Carcinoma 12 15 73
Neoplasm of Nasal Cavity 12 73
Nasal Cavity Neoplasm 12 15
Malignant Neoplasm of Nasal Cavities 12
Malignant Tumor of the Nasal Cavity 12
Malignant Neoplasm of Nasal Cavity 73
Carcinoma of Nasal Cavity 12
Tumor of the Nasal Cavity 12
Cancer of Nasal Cavity 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10811 DOID:4931 DOID:9310
ICD10 33 C30.0
ICD9CM 35 160.0
SNOMED-CT 68 93917007

Summaries for Nasal Cavity Cancer

Disease Ontology : 12 A nasal cavity cancer that_has material basis in epithelial cells.

MalaCards based summary : Nasal Cavity Cancer, also known as nasal cavity carcinoma, is related to nasal cavity squamous cell carcinoma and nasal cavity adenocarcinoma, and has symptoms including pain and rhinorrhea. An important gene associated with Nasal Cavity Cancer is CXCL11 (C-X-C Motif Chemokine Ligand 11), and among its related pathways/superpathways is Cytoskeleton remodeling Neurofilaments. The drugs Dopamine and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Nasal Cavity Cancer

Diseases in the Nasal Cavity Cancer family:

Nasal Cavity Carcinoma in Situ

Diseases related to Nasal Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
# Related Disease Score Top Affiliating Genes
1 nasal cavity squamous cell carcinoma 31.2 KRT8 KRT7 CXCL11 CDKN2A
2 nasal cavity adenocarcinoma 30.9 PDYN KRT7 CXCL11 CDX2 CDKN2A
3 inverted papilloma 29.7 CDKN2A KRT7
4 papilloma 29.5 KRT8 KRT7 CDKN2A
5 nasal cavity carcinoma in situ 12.4
6 nasal cavity cancer, childhood 12.3
7 olfactory neuroblastoma 10.4
8 middle ear carcinoma 10.4
9 hemangiopericytoma, malignant 10.3
10 ovary neuroendocrine neoplasm 10.1 KRT7 CDX2
11 appendix adenocarcinoma 10.1 KRT7 CDX2
12 anus adenocarcinoma 10.1 KRT7 CDX2
13 mucinous adenofibroma 10.1 KRT7 CDX2
14 glandular cystitis 10.1 KRT7 CDX2
15 epithelial predominant wilms' tumor 10.1 KRT7 CDX2
16 inflammatory myofibroblastic tumor 10.1
17 duodenum adenocarcinoma 10.1 KRT7 CDX2
18 gastric diffuse adenocarcinoma 10.1 KRT7 CDX2
19 appendix disease 10.1 KRT7 CDX2
20 thymus adenocarcinoma 10.1 KRT7 CDX2
21 ovarian mucinous adenocarcinoma 10.1 KRT7 CDX2
22 jejunal adenocarcinoma 10.1 KRT7 CDX2
23 bladder adenocarcinoma 10.1 KRT7 CDX2
24 chronic cystitis 10.1 KRT7 CDX2
25 anal canal adenocarcinoma 10.1 KRT7 CDX2
26 rectum adenocarcinoma 10.1 KRT7 CDX2
27 mucinous ovarian cystadenoma 10.1 KRT7 CDX2
28 biliary papillomatosis 10.1 KRT7 CDX2
29 ampulla of vater adenocarcinoma 10.1 KRT7 CDX2
30 duodenal disease 10.1 KRT7 CDX2
31 ovarian mucinous neoplasm 10.1 KRT7 CDX2
32 prostatic acinar adenocarcinoma 10.1 KRT7 CDX2
33 appendix cancer 10.1 KRT7 CDX2
34 cystic teratoma 10.1 KRT7 CDX2
35 teratoma 10.1 CDX2 KRT7
36 horseshoe kidney 10.1 KRT7 CDX2
37 proliferating trichilemmal cyst 10.1 KRT8 KRT7
38 hidradenocarcinoma 10.1 KRT7 CDX2
39 endolymphatic sac tumor 10.1 KRT8 KRT7
40 duodenum cancer 10.1 KRT7 CDX2
41 hidrocystoma 10.1 KRT8 KRT7
42 adenoid squamous cell carcinoma 10.1 KRT8 KRT7
43 pseudomyxoma peritonei 10.1 KRT7 CDX2
44 cutaneous adenocystic carcinoma 10.1 KRT8 KRT7
45 apocrine sweat gland neoplasm 10.1 KRT8 KRT7
46 cecum adenocarcinoma 10.1 KRT7 CDX2
47 signet ring cell adenocarcinoma 10.1 CDX2 KRT7
48 cystitis cystica 10.1 CDX2 KRT7
49 ampulla of vater cancer 10.1 CDX2 KRT7
50 brooke-spiegler syndrome 10.1 KRT8 KRT7

Graphical network of the top 20 diseases related to Nasal Cavity Cancer:



Diseases related to Nasal Cavity Cancer

Symptoms & Phenotypes for Nasal Cavity Cancer

UMLS symptoms related to Nasal Cavity Cancer:


pain, rhinorrhea

GenomeRNAi Phenotypes related to Nasal Cavity Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.23 KRT8
2 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.23 KRT7 KRT8
3 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.23 KRT7 KRT8
4 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.23 KRT8
5 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.23 KRT7 KRT8

MGI Mouse Phenotypes related to Nasal Cavity Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 8.92 CDKN2A CDX2 KRT8 PDYN

Drugs & Therapeutics for Nasal Cavity Cancer

Drugs for Nasal Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
2
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
3
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
4 Liver Extracts Phase 4,Phase 2,Not Applicable
5 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
6 Antidepressive Agents Phase 4,Phase 2
7 Antidepressive Agents, Second-Generation Phase 4,Phase 2
8 Dopamine Uptake Inhibitors Phase 4,Phase 2
9 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
10 Psychotropic Drugs Phase 4,Phase 2
11 Dopamine Agents Phase 4,Phase 2
12 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
13 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
15 Nicotinic Agonists Phase 4,Not Applicable
16 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
17 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
18 Central Nervous System Stimulants Phase 4,Not Applicable
19
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
20
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 2767 441203 84093
21
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
22
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
23
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
24 Antimitotic Agents Phase 3,Phase 1,Phase 2,Not Applicable
25 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
26 Immunologic Factors Phase 3,Phase 1,Phase 2
27 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
28 Antimetabolites Phase 3,Phase 1,Phase 2
29 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
30 Muscarinic Agonists Phase 2, Phase 3
31
Paclitaxel Approved, Vet_approved Phase 1, Phase 2,Phase 2,Not Applicable 33069-62-4 36314
32
Amifostine Approved, Investigational Phase 1, Phase 2,Phase 2 20537-88-6 2141
33
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
34
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
35
Indinavir Approved Phase 2 150378-17-9 5362440
36
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
37 Raspberry Approved Phase 1, Phase 2
38
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
39
Zinc Approved, Investigational Phase 2 7440-66-6
40
Zinc oxide Approved Phase 2 1314-13-2
41
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
42
Nivolumab Approved Phase 2 946414-94-4
43 Antineoplastic Agents, Phytogenic Phase 1, Phase 2,Phase 2,Not Applicable
44 Radiation-Protective Agents Phase 1, Phase 2,Phase 2
45 Protective Agents Phase 1, Phase 2,Phase 2
46 Albumin-Bound Paclitaxel Phase 1, Phase 2,Phase 2,Not Applicable
47 Antiviral Agents Phase 1, Phase 2,Phase 2
48 Anti-Infective Agents Phase 1, Phase 2,Phase 2,Not Applicable
49 Anti-HIV Agents Phase 2
50 HIV Protease Inhibitors Phase 2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
4 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
5 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
6 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
7 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
8 Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
9 Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
10 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer Completed NCT00462735 Phase 2 Cetuximab;Hydroxyurea;Fluorouracil
12 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
13 Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00002951 Phase 2 fluorouracil;hydroxyurea
14 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Completed NCT00052611 Phase 2 Celecoxib
15 Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract Completed NCT00524017 Phase 2
16 Bupropion in Helping Adults Stop Smoking Completed NCT00534001 Phase 2 bupropion hydrochloride
17 Zinc Supplements in Lowering Cadmium Levels in Smokers Completed NCT00376987 Phase 2
18 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Completed NCT00833261 Phase 2 cetuximab;cisplatin
19 Docetaxel, Cisplatin and Fluorouracil in Treating Participants With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer Recruiting NCT00707473 Phase 2 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
20 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
21 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
22 Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer Terminated NCT00003489 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
23 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer Unknown status NCT00004097 Phase 1 fluorouracil;gemcitabine hydrochloride;paclitaxel
24 Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors Unknown status NCT00978081 Phase 1 aminolevulinic acid hydrochloride
25 Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Completed NCT00036790 Phase 1 doxorubicin hydrochloride;motexafin gadolinium
26 L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors Completed NCT00003430 Phase 1 L-778,123
27 EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma Terminated NCT00004261 Phase 1 EF5
28 ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
29 Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer Unknown status NCT01254591 Not Applicable
30 Photon/Proton Radiation Therapy for Cancers of the Nasal Cavity and/or Paranasal Sinuses Completed NCT00797498
31 Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer Completed NCT00019201 Not Applicable
32 Acceptability of Less Harmful Alternatives to Cigarettes Completed NCT00957424 Not Applicable nicotine replacement therapy
33 Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking Completed NCT00790569 Not Applicable nicotine;varenicline
34 Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic Completed NCT00533884
35 Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy Completed NCT00310115
36 Computer-Assisted Scheduling of Nicotine Inhaler Use in Participants Who Plan to Stop Smoking Completed NCT00021138 Not Applicable nicotine
37 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
38 Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer Recruiting NCT02589938 Not Applicable
39 Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers Recruiting NCT00900419
40 Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use Active, not recruiting NCT00799669
41 Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure Active, not recruiting NCT00530049
42 Electroacupuncture in Treating Chronic Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Terminated NCT00623129 Not Applicable
43 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors Withdrawn NCT00499291 Not Applicable paclitaxel albumin-stabilized nanoparticle formulation

Search NIH Clinical Center for Nasal Cavity Cancer

Genetic Tests for Nasal Cavity Cancer

Anatomical Context for Nasal Cavity Cancer

MalaCards organs/tissues related to Nasal Cavity Cancer:

41
Lung, Prostate, Kidney, Liver, Bone, Thymus, Small Intestine

Publications for Nasal Cavity Cancer

Articles related to Nasal Cavity Cancer:

(show all 11)
# Title Authors Year
1
(P092) definitive chemoradiotherapy or radiotherapy for unresectable, very locally advanced, or medically inoperable paranasal sinus and nasal cavity cancer. ( 25930909 )
2015
2
Stage III-IV sinonasal and nasal cavity carcinoma treated with three-dimensional conformal radiotherapy. ( 18705398 )
2008
3
Prognostic factors in maxillary sinus and nasal cavity carcinoma. ( 15923101 )
2005
4
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Health Professional Version ( 26425762 )
2002
5
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Patient Version ( 27559600 )
2002
6
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Patient Version ( 26389439 )
2002
7
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Patient Version ( 27195380 )
2002
8
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Health Professional Version ( 26389272 )
2002
9
Ethmoid and upper nasal cavity carcinoma: treatment, results and complications. ( 2123986 )
1990
10
Nasal obstruction portending nasal cavity cancer. ( 2599810 )
1989
11
Paranasal sinuses and nasal cavity cancer: different radiotherapeutic options, results and late damages. ( 3810867 )
1986

Variations for Nasal Cavity Cancer

Expression for Nasal Cavity Cancer

Search GEO for disease gene expression data for Nasal Cavity Cancer.

Pathways for Nasal Cavity Cancer

Pathways related to Nasal Cavity Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.66 KRT7 KRT8

GO Terms for Nasal Cavity Cancer

Cellular components related to Nasal Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratin filament GO:0045095 8.62 KRT7 KRT8

Sources for Nasal Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....